PBP1510: First-in-Class Pancreatic Cancer Treatment

0 Views

07/13/23

Pancreatic cancer is one of the deadliest cancers, where less than 10% of patients survive more than 5 years.

Pancreatic Adenocarcinoma Upregulated Factor (PAUF) plays a key role in the rapid progression and metastasis of pancreatic cancer and the limited efficacy of treatment modalities. Hence, a targeted molecular therapy against PAUF is believed to be a novel cure that can save many lives.

Prestige Biopharma’s first-in-class anti-PAUF monoclonal antibody PBP1510 (INN-Ulenistamab), effectively counteracts the effects induced by PAUF, thus creating a more responsive environment for antitumor immunotherapy. Watch the full video to learn more about PBP1510.